Global Recombinant Protein Drug R & D Market Research Report 2023
According to QYResearch’s new survey, global Recombinant Protein Drug R & D market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. The global recombinant protein drug R&D market is expected to witness substantial growth due to the increasing demand for targeted and personalized therapies, advancements in biotechnology, and ongoing efforts to address unmet medical needs. The market will continue to evolve as new discoveries are made and innovative therapeutic strategies emerge from ongoing research and development activities.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Protein Drug R & D market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. The global recombinant protein drug R&D market is expected to witness substantial growth due to the increasing demand for targeted and personalized therapies, advancements in biotechnology, and ongoing efforts to address unmet medical needs. The market will continue to evolve as new discoveries are made and innovative therapeutic strategies emerge from ongoing research and development activities.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Protein Drug R & D market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Eli Lilly
- Novo Nordisk
- Amgen
- Merck
- Sanofi
- Pfizer
- Roche
- Gensci
- Ankebio
- United Cell
- Sinobioway Hygene
- Kexing
- Dongbao
- 3sbio
- Gan&Lee
- Hengrui
- Peptide Hormones
- Hematopoietic Factor
- Cytokines
- Plasma Protein Factor
- Recombinase
- Fusion Protein
- Other
- Diabetes
- Dwarfism
- Hemophilia
- Heart Disease
- Cancer
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Protein Drug R & D Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Peptide Hormones
1.2.3 Hematopoietic Factor
1.2.4 Cytokines
1.2.5 Plasma Protein Factor
1.2.6 Recombinase
1.2.7 Fusion Protein
1.2.8 Other
1.3 Market by Application
1.3.1 Global Recombinant Protein Drug R & D Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Diabetes
1.3.3 Dwarfism
1.3.4 Hemophilia
1.3.5 Heart Disease
1.3.6 Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Recombinant Protein Drug R & D Market Perspective (2018-2029)
2.2 Recombinant Protein Drug R & D Growth Trends by Region
2.2.1 Global Recombinant Protein Drug R & D Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Recombinant Protein Drug R & D Historic Market Size by Region (2018-2023)
2.2.3 Recombinant Protein Drug R & D Forecasted Market Size by Region (2024-2029)
2.3 Recombinant Protein Drug R & D Market Dynamics
2.3.1 Recombinant Protein Drug R & D Industry Trends
2.3.2 Recombinant Protein Drug R & D Market Drivers
2.3.3 Recombinant Protein Drug R & D Market Challenges
2.3.4 Recombinant Protein Drug R & D Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Recombinant Protein Drug R & D Players by Revenue
3.1.1 Global Top Recombinant Protein Drug R & D Players by Revenue (2018-2023)
3.1.2 Global Recombinant Protein Drug R & D Revenue Market Share by Players (2018-2023)
3.2 Global Recombinant Protein Drug R & D Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Protein Drug R & D Revenue
3.4 Global Recombinant Protein Drug R & D Market Concentration Ratio
3.4.1 Global Recombinant Protein Drug R & D Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Protein Drug R & D Revenue in 2022
3.5 Recombinant Protein Drug R & D Key Players Head office and Area Served
3.6 Key Players Recombinant Protein Drug R & D Product Solution and Service
3.7 Date of Enter into Recombinant Protein Drug R & D Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RECOMBINANT PROTEIN DRUG R & D BREAKDOWN DATA BY TYPE
4.1 Global Recombinant Protein Drug R & D Historic Market Size by Type (2018-2023)
4.2 Global Recombinant Protein Drug R & D Forecasted Market Size by Type (2024-2029)
5 RECOMBINANT PROTEIN DRUG R & D BREAKDOWN DATA BY APPLICATION
5.1 Global Recombinant Protein Drug R & D Historic Market Size by Application (2018-2023)
5.2 Global Recombinant Protein Drug R & D Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Recombinant Protein Drug R & D Market Size (2018-2029)
6.2 North America Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Recombinant Protein Drug R & D Market Size by Country (2018-2023)
6.4 North America Recombinant Protein Drug R & D Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Recombinant Protein Drug R & D Market Size (2018-2029)
7.2 Europe Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Recombinant Protein Drug R & D Market Size by Country (2018-2023)
7.4 Europe Recombinant Protein Drug R & D Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Recombinant Protein Drug R & D Market Size (2018-2029)
8.2 Asia-Pacific Recombinant Protein Drug R & D Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2018-2023)
8.4 Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Recombinant Protein Drug R & D Market Size (2018-2029)
9.2 Latin America Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Recombinant Protein Drug R & D Market Size by Country (2018-2023)
9.4 Latin America Recombinant Protein Drug R & D Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Recombinant Protein Drug R & D Market Size (2018-2029)
10.2 Middle East & Africa Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2018-2023)
10.4 Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Recombinant Protein Drug R & D Introduction
11.1.4 Eli Lilly Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.1.5 Eli Lilly Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Recombinant Protein Drug R & D Introduction
11.2.4 Novo Nordisk Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.2.5 Novo Nordisk Recent Development
11.3 Amgen
11.3.1 Amgen Company Detail
11.3.2 Amgen Business Overview
11.3.3 Amgen Recombinant Protein Drug R & D Introduction
11.3.4 Amgen Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.3.5 Amgen Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Recombinant Protein Drug R & D Introduction
11.4.4 Merck Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Recombinant Protein Drug R & D Introduction
11.5.4 Sanofi Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Recombinant Protein Drug R & D Introduction
11.6.4 Pfizer Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Recombinant Protein Drug R & D Introduction
11.7.4 Roche Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.7.5 Roche Recent Development
11.8 Gensci
11.8.1 Gensci Company Detail
11.8.2 Gensci Business Overview
11.8.3 Gensci Recombinant Protein Drug R & D Introduction
11.8.4 Gensci Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.8.5 Gensci Recent Development
11.9 Ankebio
11.9.1 Ankebio Company Detail
11.9.2 Ankebio Business Overview
11.9.3 Ankebio Recombinant Protein Drug R & D Introduction
11.9.4 Ankebio Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.9.5 Ankebio Recent Development
11.10 United Cell
11.10.1 United Cell Company Detail
11.10.2 United Cell Business Overview
11.10.3 United Cell Recombinant Protein Drug R & D Introduction
11.10.4 United Cell Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.10.5 United Cell Recent Development
11.11 Sinobioway Hygene
11.11.1 Sinobioway Hygene Company Detail
11.11.2 Sinobioway Hygene Business Overview
11.11.3 Sinobioway Hygene Recombinant Protein Drug R & D Introduction
11.11.4 Sinobioway Hygene Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.11.5 Sinobioway Hygene Recent Development
11.12 Kexing
11.12.1 Kexing Company Detail
11.12.2 Kexing Business Overview
11.12.3 Kexing Recombinant Protein Drug R & D Introduction
11.12.4 Kexing Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.12.5 Kexing Recent Development
11.13 Dongbao
11.13.1 Dongbao Company Detail
11.13.2 Dongbao Business Overview
11.13.3 Dongbao Recombinant Protein Drug R & D Introduction
11.13.4 Dongbao Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.13.5 Dongbao Recent Development
11.14 3sbio
11.14.1 3sbio Company Detail
11.14.2 3sbio Business Overview
11.14.3 3sbio Recombinant Protein Drug R & D Introduction
11.14.4 3sbio Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.14.5 3sbio Recent Development
11.15 Gan&Lee
11.15.1 Gan&Lee Company Detail
11.15.2 Gan&Lee Business Overview
11.15.3 Gan&Lee Recombinant Protein Drug R & D Introduction
11.15.4 Gan&Lee Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.15.5 Gan&Lee Recent Development
11.16 Hengrui
11.16.1 Hengrui Company Detail
11.16.2 Hengrui Business Overview
11.16.3 Hengrui Recombinant Protein Drug R & D Introduction
11.16.4 Hengrui Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.16.5 Hengrui Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Protein Drug R & D Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Peptide Hormones
1.2.3 Hematopoietic Factor
1.2.4 Cytokines
1.2.5 Plasma Protein Factor
1.2.6 Recombinase
1.2.7 Fusion Protein
1.2.8 Other
1.3 Market by Application
1.3.1 Global Recombinant Protein Drug R & D Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Diabetes
1.3.3 Dwarfism
1.3.4 Hemophilia
1.3.5 Heart Disease
1.3.6 Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Recombinant Protein Drug R & D Market Perspective (2018-2029)
2.2 Recombinant Protein Drug R & D Growth Trends by Region
2.2.1 Global Recombinant Protein Drug R & D Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Recombinant Protein Drug R & D Historic Market Size by Region (2018-2023)
2.2.3 Recombinant Protein Drug R & D Forecasted Market Size by Region (2024-2029)
2.3 Recombinant Protein Drug R & D Market Dynamics
2.3.1 Recombinant Protein Drug R & D Industry Trends
2.3.2 Recombinant Protein Drug R & D Market Drivers
2.3.3 Recombinant Protein Drug R & D Market Challenges
2.3.4 Recombinant Protein Drug R & D Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Recombinant Protein Drug R & D Players by Revenue
3.1.1 Global Top Recombinant Protein Drug R & D Players by Revenue (2018-2023)
3.1.2 Global Recombinant Protein Drug R & D Revenue Market Share by Players (2018-2023)
3.2 Global Recombinant Protein Drug R & D Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Protein Drug R & D Revenue
3.4 Global Recombinant Protein Drug R & D Market Concentration Ratio
3.4.1 Global Recombinant Protein Drug R & D Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Protein Drug R & D Revenue in 2022
3.5 Recombinant Protein Drug R & D Key Players Head office and Area Served
3.6 Key Players Recombinant Protein Drug R & D Product Solution and Service
3.7 Date of Enter into Recombinant Protein Drug R & D Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RECOMBINANT PROTEIN DRUG R & D BREAKDOWN DATA BY TYPE
4.1 Global Recombinant Protein Drug R & D Historic Market Size by Type (2018-2023)
4.2 Global Recombinant Protein Drug R & D Forecasted Market Size by Type (2024-2029)
5 RECOMBINANT PROTEIN DRUG R & D BREAKDOWN DATA BY APPLICATION
5.1 Global Recombinant Protein Drug R & D Historic Market Size by Application (2018-2023)
5.2 Global Recombinant Protein Drug R & D Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Recombinant Protein Drug R & D Market Size (2018-2029)
6.2 North America Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Recombinant Protein Drug R & D Market Size by Country (2018-2023)
6.4 North America Recombinant Protein Drug R & D Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Recombinant Protein Drug R & D Market Size (2018-2029)
7.2 Europe Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Recombinant Protein Drug R & D Market Size by Country (2018-2023)
7.4 Europe Recombinant Protein Drug R & D Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Recombinant Protein Drug R & D Market Size (2018-2029)
8.2 Asia-Pacific Recombinant Protein Drug R & D Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2018-2023)
8.4 Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Recombinant Protein Drug R & D Market Size (2018-2029)
9.2 Latin America Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Recombinant Protein Drug R & D Market Size by Country (2018-2023)
9.4 Latin America Recombinant Protein Drug R & D Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Recombinant Protein Drug R & D Market Size (2018-2029)
10.2 Middle East & Africa Recombinant Protein Drug R & D Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2018-2023)
10.4 Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Recombinant Protein Drug R & D Introduction
11.1.4 Eli Lilly Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.1.5 Eli Lilly Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Recombinant Protein Drug R & D Introduction
11.2.4 Novo Nordisk Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.2.5 Novo Nordisk Recent Development
11.3 Amgen
11.3.1 Amgen Company Detail
11.3.2 Amgen Business Overview
11.3.3 Amgen Recombinant Protein Drug R & D Introduction
11.3.4 Amgen Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.3.5 Amgen Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Recombinant Protein Drug R & D Introduction
11.4.4 Merck Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Recombinant Protein Drug R & D Introduction
11.5.4 Sanofi Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Recombinant Protein Drug R & D Introduction
11.6.4 Pfizer Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Recombinant Protein Drug R & D Introduction
11.7.4 Roche Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.7.5 Roche Recent Development
11.8 Gensci
11.8.1 Gensci Company Detail
11.8.2 Gensci Business Overview
11.8.3 Gensci Recombinant Protein Drug R & D Introduction
11.8.4 Gensci Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.8.5 Gensci Recent Development
11.9 Ankebio
11.9.1 Ankebio Company Detail
11.9.2 Ankebio Business Overview
11.9.3 Ankebio Recombinant Protein Drug R & D Introduction
11.9.4 Ankebio Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.9.5 Ankebio Recent Development
11.10 United Cell
11.10.1 United Cell Company Detail
11.10.2 United Cell Business Overview
11.10.3 United Cell Recombinant Protein Drug R & D Introduction
11.10.4 United Cell Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.10.5 United Cell Recent Development
11.11 Sinobioway Hygene
11.11.1 Sinobioway Hygene Company Detail
11.11.2 Sinobioway Hygene Business Overview
11.11.3 Sinobioway Hygene Recombinant Protein Drug R & D Introduction
11.11.4 Sinobioway Hygene Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.11.5 Sinobioway Hygene Recent Development
11.12 Kexing
11.12.1 Kexing Company Detail
11.12.2 Kexing Business Overview
11.12.3 Kexing Recombinant Protein Drug R & D Introduction
11.12.4 Kexing Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.12.5 Kexing Recent Development
11.13 Dongbao
11.13.1 Dongbao Company Detail
11.13.2 Dongbao Business Overview
11.13.3 Dongbao Recombinant Protein Drug R & D Introduction
11.13.4 Dongbao Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.13.5 Dongbao Recent Development
11.14 3sbio
11.14.1 3sbio Company Detail
11.14.2 3sbio Business Overview
11.14.3 3sbio Recombinant Protein Drug R & D Introduction
11.14.4 3sbio Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.14.5 3sbio Recent Development
11.15 Gan&Lee
11.15.1 Gan&Lee Company Detail
11.15.2 Gan&Lee Business Overview
11.15.3 Gan&Lee Recombinant Protein Drug R & D Introduction
11.15.4 Gan&Lee Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.15.5 Gan&Lee Recent Development
11.16 Hengrui
11.16.1 Hengrui Company Detail
11.16.2 Hengrui Business Overview
11.16.3 Hengrui Recombinant Protein Drug R & D Introduction
11.16.4 Hengrui Revenue in Recombinant Protein Drug R & D Business (2018-2023)
11.16.5 Hengrui Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Recombinant Protein Drug R & D Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Peptide Hormones
Table 3. Key Players of Hematopoietic Factor
Table 4. Key Players of Cytokines
Table 5. Key Players of Plasma Protein Factor
Table 6. Key Players of Recombinase
Table 7. Key Players of Fusion Protein
Table 8. Key Players of Other
Table 9. Global Recombinant Protein Drug R & D Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Recombinant Protein Drug R & D Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 11. Global Recombinant Protein Drug R & D Market Size by Region (2018-2023) & (US$ Million)
Table 12. Global Recombinant Protein Drug R & D Market Share by Region (2018-2023)
Table 13. Global Recombinant Protein Drug R & D Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 14. Global Recombinant Protein Drug R & D Market Share by Region (2024-2029)
Table 15. Recombinant Protein Drug R & D Market Trends
Table 16. Recombinant Protein Drug R & D Market Drivers
Table 17. Recombinant Protein Drug R & D Market Challenges
Table 18. Recombinant Protein Drug R & D Market Restraints
Table 19. Global Recombinant Protein Drug R & D Revenue by Players (2018-2023) & (US$ Million)
Table 20. Global Recombinant Protein Drug R & D Market Share by Players (2018-2023)
Table 21. Global Top Recombinant Protein Drug R & D Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drug R & D as of 2022)
Table 22. Ranking of Global Top Recombinant Protein Drug R & D Companies by Revenue (US$ Million) in 2022
Table 23. Global 5 Largest Players Market Share by Recombinant Protein Drug R & D Revenue (CR5 and HHI) & (2018-2023)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Recombinant Protein Drug R & D Product Solution and Service
Table 26. Date of Enter into Recombinant Protein Drug R & D Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Recombinant Protein Drug R & D Market Size by Type (2018-2023) & (US$ Million)
Table 29. Global Recombinant Protein Drug R & D Revenue Market Share by Type (2018-2023)
Table 30. Global Recombinant Protein Drug R & D Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 31. Global Recombinant Protein Drug R & D Revenue Market Share by Type (2024-2029)
Table 32. Global Recombinant Protein Drug R & D Market Size by Application (2018-2023) & (US$ Million)
Table 33. Global Recombinant Protein Drug R & D Revenue Market Share by Application (2018-2023)
Table 34. Global Recombinant Protein Drug R & D Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 35. Global Recombinant Protein Drug R & D Revenue Market Share by Application (2024-2029)
Table 36. North America Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 40. Europe Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 41. Europe Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 42. Asia-Pacific Recombinant Protein Drug R & D Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 43. Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2018-2023) & (US$ Million)
Table 44. Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2024-2029) & (US$ Million)
Table 45. Latin America Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Latin America Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 47. Latin America Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 48. Middle East & Africa Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 49. Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 50. Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 51. Eli Lilly Company Detail
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Recombinant Protein Drug R & D Product
Table 54. Eli Lilly Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 55. Eli Lilly Recent Development
Table 56. Novo Nordisk Company Detail
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk Recombinant Protein Drug R & D Product
Table 59. Novo Nordisk Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 60. Novo Nordisk Recent Development
Table 61. Amgen Company Detail
Table 62. Amgen Business Overview
Table 63. Amgen Recombinant Protein Drug R & D Product
Table 64. Amgen Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Merck Company Detail
Table 67. Merck Business Overview
Table 68. Merck Recombinant Protein Drug R & D Product
Table 69. Merck Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Sanofi Company Detail
Table 72. Sanofi Business Overview
Table 73. Sanofi Recombinant Protein Drug R & D Product
Table 74. Sanofi Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 75. Sanofi Recent Development
Table 76. Pfizer Company Detail
Table 77. Pfizer Business Overview
Table 78. Pfizer Recombinant Protein Drug R & D Product
Table 79. Pfizer Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Roche Company Detail
Table 82. Roche Business Overview
Table 83. Roche Recombinant Protein Drug R & D Product
Table 84. Roche Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 85. Roche Recent Development
Table 86. Gensci Company Detail
Table 87. Gensci Business Overview
Table 88. Gensci Recombinant Protein Drug R & D Product
Table 89. Gensci Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 90. Gensci Recent Development
Table 91. Ankebio Company Detail
Table 92. Ankebio Business Overview
Table 93. Ankebio Recombinant Protein Drug R & D Product
Table 94. Ankebio Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 95. Ankebio Recent Development
Table 96. United Cell Company Detail
Table 97. United Cell Business Overview
Table 98. United Cell Recombinant Protein Drug R & D Product
Table 99. United Cell Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 100. United Cell Recent Development
Table 101. Sinobioway Hygene Company Detail
Table 102. Sinobioway Hygene Business Overview
Table 103. Sinobioway Hygene Recombinant Protein Drug R & D Product
Table 104. Sinobioway Hygene Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 105. Sinobioway Hygene Recent Development
Table 106. Kexing Company Detail
Table 107. Kexing Business Overview
Table 108. Kexing Recombinant Protein Drug R & D Product
Table 109. Kexing Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 110. Kexing Recent Development
Table 111. Dongbao Company Detail
Table 112. Dongbao Business Overview
Table 113. Dongbao Recombinant Protein Drug R & D Product
Table 114. Dongbao Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 115. Dongbao Recent Development
Table 116. 3sbio Company Detail
Table 117. 3sbio Business Overview
Table 118. 3sbio Recombinant Protein Drug R & D Product
Table 119. 3sbio Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 120. 3sbio Recent Development
Table 121. Gan&Lee Company Detail
Table 122. Gan&Lee Business Overview
Table 123. Gan&Lee Recombinant Protein Drug R & D Product
Table 124. Gan&Lee Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 125. Gan&Lee Recent Development
Table 126. Hengrui Company Detail
Table 127. Hengrui Business Overview
Table 128. Hengrui Recombinant Protein Drug R & D Product
Table 129. Hengrui Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 130. Hengrui Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
Table 1. Global Recombinant Protein Drug R & D Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Peptide Hormones
Table 3. Key Players of Hematopoietic Factor
Table 4. Key Players of Cytokines
Table 5. Key Players of Plasma Protein Factor
Table 6. Key Players of Recombinase
Table 7. Key Players of Fusion Protein
Table 8. Key Players of Other
Table 9. Global Recombinant Protein Drug R & D Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Recombinant Protein Drug R & D Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 11. Global Recombinant Protein Drug R & D Market Size by Region (2018-2023) & (US$ Million)
Table 12. Global Recombinant Protein Drug R & D Market Share by Region (2018-2023)
Table 13. Global Recombinant Protein Drug R & D Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 14. Global Recombinant Protein Drug R & D Market Share by Region (2024-2029)
Table 15. Recombinant Protein Drug R & D Market Trends
Table 16. Recombinant Protein Drug R & D Market Drivers
Table 17. Recombinant Protein Drug R & D Market Challenges
Table 18. Recombinant Protein Drug R & D Market Restraints
Table 19. Global Recombinant Protein Drug R & D Revenue by Players (2018-2023) & (US$ Million)
Table 20. Global Recombinant Protein Drug R & D Market Share by Players (2018-2023)
Table 21. Global Top Recombinant Protein Drug R & D Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drug R & D as of 2022)
Table 22. Ranking of Global Top Recombinant Protein Drug R & D Companies by Revenue (US$ Million) in 2022
Table 23. Global 5 Largest Players Market Share by Recombinant Protein Drug R & D Revenue (CR5 and HHI) & (2018-2023)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Recombinant Protein Drug R & D Product Solution and Service
Table 26. Date of Enter into Recombinant Protein Drug R & D Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Recombinant Protein Drug R & D Market Size by Type (2018-2023) & (US$ Million)
Table 29. Global Recombinant Protein Drug R & D Revenue Market Share by Type (2018-2023)
Table 30. Global Recombinant Protein Drug R & D Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 31. Global Recombinant Protein Drug R & D Revenue Market Share by Type (2024-2029)
Table 32. Global Recombinant Protein Drug R & D Market Size by Application (2018-2023) & (US$ Million)
Table 33. Global Recombinant Protein Drug R & D Revenue Market Share by Application (2018-2023)
Table 34. Global Recombinant Protein Drug R & D Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 35. Global Recombinant Protein Drug R & D Revenue Market Share by Application (2024-2029)
Table 36. North America Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 40. Europe Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 41. Europe Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 42. Asia-Pacific Recombinant Protein Drug R & D Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 43. Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2018-2023) & (US$ Million)
Table 44. Asia-Pacific Recombinant Protein Drug R & D Market Size by Region (2024-2029) & (US$ Million)
Table 45. Latin America Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Latin America Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 47. Latin America Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 48. Middle East & Africa Recombinant Protein Drug R & D Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 49. Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2018-2023) & (US$ Million)
Table 50. Middle East & Africa Recombinant Protein Drug R & D Market Size by Country (2024-2029) & (US$ Million)
Table 51. Eli Lilly Company Detail
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Recombinant Protein Drug R & D Product
Table 54. Eli Lilly Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 55. Eli Lilly Recent Development
Table 56. Novo Nordisk Company Detail
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk Recombinant Protein Drug R & D Product
Table 59. Novo Nordisk Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 60. Novo Nordisk Recent Development
Table 61. Amgen Company Detail
Table 62. Amgen Business Overview
Table 63. Amgen Recombinant Protein Drug R & D Product
Table 64. Amgen Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Merck Company Detail
Table 67. Merck Business Overview
Table 68. Merck Recombinant Protein Drug R & D Product
Table 69. Merck Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Sanofi Company Detail
Table 72. Sanofi Business Overview
Table 73. Sanofi Recombinant Protein Drug R & D Product
Table 74. Sanofi Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 75. Sanofi Recent Development
Table 76. Pfizer Company Detail
Table 77. Pfizer Business Overview
Table 78. Pfizer Recombinant Protein Drug R & D Product
Table 79. Pfizer Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Roche Company Detail
Table 82. Roche Business Overview
Table 83. Roche Recombinant Protein Drug R & D Product
Table 84. Roche Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 85. Roche Recent Development
Table 86. Gensci Company Detail
Table 87. Gensci Business Overview
Table 88. Gensci Recombinant Protein Drug R & D Product
Table 89. Gensci Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 90. Gensci Recent Development
Table 91. Ankebio Company Detail
Table 92. Ankebio Business Overview
Table 93. Ankebio Recombinant Protein Drug R & D Product
Table 94. Ankebio Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 95. Ankebio Recent Development
Table 96. United Cell Company Detail
Table 97. United Cell Business Overview
Table 98. United Cell Recombinant Protein Drug R & D Product
Table 99. United Cell Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 100. United Cell Recent Development
Table 101. Sinobioway Hygene Company Detail
Table 102. Sinobioway Hygene Business Overview
Table 103. Sinobioway Hygene Recombinant Protein Drug R & D Product
Table 104. Sinobioway Hygene Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 105. Sinobioway Hygene Recent Development
Table 106. Kexing Company Detail
Table 107. Kexing Business Overview
Table 108. Kexing Recombinant Protein Drug R & D Product
Table 109. Kexing Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 110. Kexing Recent Development
Table 111. Dongbao Company Detail
Table 112. Dongbao Business Overview
Table 113. Dongbao Recombinant Protein Drug R & D Product
Table 114. Dongbao Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 115. Dongbao Recent Development
Table 116. 3sbio Company Detail
Table 117. 3sbio Business Overview
Table 118. 3sbio Recombinant Protein Drug R & D Product
Table 119. 3sbio Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 120. 3sbio Recent Development
Table 121. Gan&Lee Company Detail
Table 122. Gan&Lee Business Overview
Table 123. Gan&Lee Recombinant Protein Drug R & D Product
Table 124. Gan&Lee Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 125. Gan&Lee Recent Development
Table 126. Hengrui Company Detail
Table 127. Hengrui Business Overview
Table 128. Hengrui Recombinant Protein Drug R & D Product
Table 129. Hengrui Revenue in Recombinant Protein Drug R & D Business (2018-2023) & (US$ Million)
Table 130. Hengrui Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Recombinant Protein Drug R & D Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Recombinant Protein Drug R & D Market Share by Type: 2022 VS 2029
Figure 3. Peptide Hormones Features
Figure 4. Hematopoietic Factor Features
Figure 5. Cytokines Features
Figure 6. Plasma Protein Factor Features
Figure 7. Recombinase Features
Figure 8. Fusion Protein Features
Figure 9. Other Features
Figure 10. Global Recombinant Protein Drug R & D Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 11. Global Recombinant Protein Drug R & D Market Share by Application: 2022 VS 2029
Figure 12. Diabetes Case Studies
Figure 13. Dwarfism Case Studies
Figure 14. Hemophilia Case Studies
Figure 15. Heart Disease Case Studies
Figure 16. Cancer Case Studies
Figure 17. Other Case Studies
Figure 18. Recombinant Protein Drug R & D Report Years Considered
Figure 19. Global Recombinant Protein Drug R & D Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 20. Global Recombinant Protein Drug R & D Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 21. Global Recombinant Protein Drug R & D Market Share by Region: 2022 VS 2029
Figure 22. Global Recombinant Protein Drug R & D Market Share by Players in 2022
Figure 23. Global Top Recombinant Protein Drug R & D Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drug R & D as of 2022)
Figure 24. The Top 10 and 5 Players Market Share by Recombinant Protein Drug R & D Revenue in 2022
Figure 25. North America Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. North America Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 27. United States Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Europe Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 31. Germany Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. France Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. U.K. Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Italy Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Russia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Nordic Countries Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Asia-Pacific Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Asia-Pacific Recombinant Protein Drug R & D Market Share by Region (2018-2029)
Figure 39. China Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Japan Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. India Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Australia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Latin America Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Latin America Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 47. Mexico Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Brazil Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 51. Turkey Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Eli Lilly Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 54. Novo Nordisk Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 55. Amgen Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 56. Merck Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 57. Sanofi Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 58. Pfizer Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 59. Roche Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 60. Gensci Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 61. Ankebio Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 62. United Cell Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 63. Sinobioway Hygene Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 64. Kexing Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 65. Dongbao Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 66. 3sbio Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 67. Gan&Lee Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 68. Hengrui Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Global Recombinant Protein Drug R & D Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Recombinant Protein Drug R & D Market Share by Type: 2022 VS 2029
Figure 3. Peptide Hormones Features
Figure 4. Hematopoietic Factor Features
Figure 5. Cytokines Features
Figure 6. Plasma Protein Factor Features
Figure 7. Recombinase Features
Figure 8. Fusion Protein Features
Figure 9. Other Features
Figure 10. Global Recombinant Protein Drug R & D Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 11. Global Recombinant Protein Drug R & D Market Share by Application: 2022 VS 2029
Figure 12. Diabetes Case Studies
Figure 13. Dwarfism Case Studies
Figure 14. Hemophilia Case Studies
Figure 15. Heart Disease Case Studies
Figure 16. Cancer Case Studies
Figure 17. Other Case Studies
Figure 18. Recombinant Protein Drug R & D Report Years Considered
Figure 19. Global Recombinant Protein Drug R & D Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 20. Global Recombinant Protein Drug R & D Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 21. Global Recombinant Protein Drug R & D Market Share by Region: 2022 VS 2029
Figure 22. Global Recombinant Protein Drug R & D Market Share by Players in 2022
Figure 23. Global Top Recombinant Protein Drug R & D Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drug R & D as of 2022)
Figure 24. The Top 10 and 5 Players Market Share by Recombinant Protein Drug R & D Revenue in 2022
Figure 25. North America Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. North America Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 27. United States Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Europe Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 31. Germany Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. France Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. U.K. Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Italy Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Russia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Nordic Countries Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Asia-Pacific Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Asia-Pacific Recombinant Protein Drug R & D Market Share by Region (2018-2029)
Figure 39. China Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Japan Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. India Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Australia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Latin America Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Latin America Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 47. Mexico Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Brazil Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Recombinant Protein Drug R & D Market Share by Country (2018-2029)
Figure 51. Turkey Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Recombinant Protein Drug R & D Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Eli Lilly Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 54. Novo Nordisk Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 55. Amgen Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 56. Merck Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 57. Sanofi Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 58. Pfizer Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 59. Roche Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 60. Gensci Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 61. Ankebio Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 62. United Cell Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 63. Sinobioway Hygene Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 64. Kexing Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 65. Dongbao Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 66. 3sbio Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 67. Gan&Lee Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 68. Hengrui Revenue Growth Rate in Recombinant Protein Drug R & D Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
